CA II, a potential biomarker by proteomic analysis, exerts significant inhibitory effect on the growth of colorectal cancer cells

International Journal of Oncology

Volumn 43, Issue 2, 2013, Pages 611-621

  Zhou, Rui ^a,c   Huang, Wenjun ^c   Yao, Yuqin ^a   Wang, Yuxi ^a   Li, Ziqiang ^a   Shao, Bin ^a   Zhong, Jian ^a   Tang, Minghai ^a   Liang, Shufang ^a   Zhao, Xia ^b   Tong, Aiping ^a   Yang, Jinliang ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

2 DE electrophoresis; Carbonic anhydrase II; Colorectal carcinoma; Matrix spectrum; Proteome; Stable cell line

Indexed keywords

ACETAZOLAMIDE; BIOLOGICAL MARKER; CARBONATE DEHYDRATASE II; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER TISSUE; CELL CYCLE ARREST; CELL GROWTH; CHEMOSENSITIVITY; COLON CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; EARLY DIAGNOSIS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN TISSUE; IC 50; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TUMOR GROWTH; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE II; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; G2 PHASE CELL CYCLE CHECKPOINTS; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879651865     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1972     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics. CA Cancer J Clin 58: 71-96, 2008.
2. Woolf SH: The best screening test for colorectal cancer - a personal choice. N Engl J Med 343: 1641-1643, 2000.
3. Walsh JM and Terdiman JP: Colorectal cancer screening: scientific review. JAMA 289: 1288-1296, 2003. (Pubitemid 37432910)
4. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005. (Pubitemid 40310185)
5. Phizicky E, Bastiaens PI, Zhu H, Snyder M and Fields S: Protein analysis on a proteomic scale. Nature 422: 208-215, 2003. (Pubitemid 36362758)
6. Alessandro R, Belluco C and Kohn EC: Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery. Clin Colorectal Cancer 4: 396-402, 2005. (Pubitemid 41268777)
7. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA and Nelson RW: Population proteomics: the concept, attributes and potential for cancer biomarker research. Mol Cell Proteomics 5: 1811-1818, 2006. (Pubitemid 44688190)
8. Tyers M and Mann M: From genomics to proteomics. Nature 422: 193-197, 2003. (Pubitemid 36362756)
9. Tong A, Zhang H, Li Z, et al: Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. Cancer Chemother Pharmacol 61: 791-802, 2008. (Pubitemid 351302035)
10. Dahan L, Sadok A, Formento JL, Seitz JF and Kovacic H: Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol 158: 610-620, 2009.
11. Gilmour KM: Perspectives on carbonic anhydrase. Comp Biochem Physiol A Mol Integr Physiol 157: 193-197, 2010.
12. Yoshiura K, Nakaoka T, Nishishita T, et al: Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol 23: 743-750, 2010.
13. Yoshiura K, Nakaoka T, Nishishita T, et al: Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. Clin Cancer Res 11: 8201-8207, 2005. (Pubitemid 41698765)
14. Haapasalo J, Nordfors K, Järvelä S, et al: Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy. Neurooncology 9: 308-313, 2007. (Pubitemid 47169663)
15. Korhonen K, Parkkila AK, Helen P, et al: Carbonic anhydrases in meningiomas: association of endothelial carbonic anhydrase II with aggressive tumor features. J Neurosurg 111: 472-477, 2009.
16. Kivela AJ, Saarnio J, Karttunen TJ, et al: Differential expression of cytoplasmic carbonic anhydrases, CA I and II and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors. Dig Dis Sci 46: 2179-2186, 2001. (Pubitemid 32955229)
17. Kummola L, Hämäläinen JM, Kivelä J, Kivelä AJ, Saarnio J, Karttunen T and Parkkila S: Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa. BMC Cancer 5: 41, 2005.
18. Niemelä AM, Hynninen P, Mecklin JP, et al: Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer. Cancer Epidemiol Biomarkers Prev 16: 1760-1766, 2007.
19. Parks SK, Chiche J and Pouyssegur J: pH control mechanisms of tumor survival and growth. J Cell Physiol 226: 299-308, 2011.
20. Swietach P, Vaughan-Jones RD and Harris AL: Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 26: 299-310, 2007. (Pubitemid 47101667)
21. Pastorekova S, Ratcliffe PJ and Pastorek J: Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia. BJU Int 101: 8-15, 2008.
22. Lv L, Li D, Zhao D, et al: Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 42: 719-730, 2011.
23. Harris I, McCracken S and Mak TW: PKM2: a gatekeeper between growth and survival. Cell Res 22: 447-449, 2012.
24. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.
25. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
26. Mallory JC, Crudden G, Oliva A, Saunders C, Stromberg A and Craven RJ: A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mol Pharmacol 68: 1747-1756, 2005. (Pubitemid 41656027)